Tag Archives: Jack Meehan

Barclays Keeps a Hold Rating on Quest Diagnostics (DGX)

Barclays analyst Jack Meehan maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $99.00. The company’s shares closed last Wednesday at $99.58. According to TipRanks.com, Meehan is a 4-star analyst with

Myriad Genetics (MYGN) Gets a Sell Rating from Barclays

Barclays analyst Jack Meehan maintained a Sell rating on Myriad Genetics (MYGN – Research Report) today and set a price target of $10.00. The company’s shares closed last Monday at $14.82, close to its 52-week low of $9.24. According to

Avantor (AVTR) Gets a Buy Rating from Barclays

In a report released today, Jack Meehan from Barclays maintained a Buy rating on Avantor (AVTR – Research Report), with a price target of $19.00. The company’s shares closed last Monday at $11.80. According to TipRanks.com, Meehan is a 4-star

InMode (INMD) Gets a Buy Rating from Barclays

Barclays analyst Jack Meehan maintained a Buy rating on InMode (INMD – Research Report) today and set a price target of $36.00. The company’s shares closed last Monday at $23.80. According to TipRanks.com, Meehan is a 4-star analyst with an

Barclays Remains a Hold on Syneos Health (SYNH)

In a report released today, Jack Meehan from Barclays maintained a Hold rating on Syneos Health (SYNH – Research Report), with a price target of $61.00. The company’s shares closed last Monday at $42.57. According to TipRanks.com, Meehan is a

Barclays Sticks to Their Hold Rating for Agilent (A)

Barclays analyst Jack Meehan maintained a Hold rating on Agilent (A – Research Report) today and set a price target of $76.00. The company’s shares closed last Monday at $72.87. According to TipRanks.com, Meehan is a 4-star analyst with an